NVS Overview
Upcoming Projects (NVS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NVS)
-
Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Tickers: SRRK, RHHBY, NVS, BIIB
Executed On: Oct 22, 2024 at 06:30 PM EDT -
A Third View: Discussing the recent FDA accelerated approval for Fabhalta® (iptacopan) in patients with IgA nephropathy (IgAN)
Ticker: NVS
Executed On: Sep 27, 2024 at 02:00 PM EDT -
A Third View: Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 26, 2024 at 09:30 AM EDT -
A Second View: Discussing the recent FDA accelerated approval for Fabhalta® (iptacopan) in patients with IgA nephropathy (IgAN)
Ticker: NVS
Executed On: Sep 25, 2024 at 09:30 AM EDT -
Discussing Novartis data showing early addition of twice-yearly* Leqvio® (inclisiran) reduces LDL-C in ASCVD patients in real-world setting.
Ticker: NVS
Executed On: Sep 16, 2024 at 12:00 PM EDT -
A Second View: Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 12, 2024 at 10:00 AM EDT -
Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 05, 2024 at 11:00 AM EDT -
Discussing the recent FDA accelerated approval for Fabhalta® (iptacopan) in patients with IgA nephropathy (IgAN)
Ticker: NVS
Executed On: Aug 22, 2024 at 02:15 PM EDT -
A Third Look: Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker: NVS
Executed On: Jul 24, 2024 at 10:00 AM EDT -
A Second Look: Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker: NVS
Executed On: Jul 22, 2024 at 08:30 AM EDT -
Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker: NVS
Executed On: Jul 19, 2024 at 09:35 AM EDT -
A Third View: Delving into the Phase 3 ALIGN clinical trial of atrasentan in patients with IgA nephropathy.
Ticker: NVS
Executed On: May 31, 2024 at 04:00 PM EDT -
A Second View: Delving into the Phase 3 ALIGN clinical trial of atrasentan in patients with IgA nephropathy.
Ticker: NVS
Executed On: May 31, 2024 at 03:00 PM EDT -
Delving into the Phase 3 ALIGN clinical trial of atrasentan in patients with IgA nephropathy.
Ticker: NVS
Executed On: May 31, 2024 at 02:00 PM EDT -
A Third Opinion: Discussing the phase 3 APPLAUSE-IgAN study results on Fabhalta (iptacopan) in patients with IgA Nephropathy
Ticker: NVS
Executed On: Apr 26, 2024 at 03:30 PM EDT -
A Second Opinion: Discussing the phase 3 APPLAUSE-IgAN study results on Fabhalta (iptacopan) in patients with IgA Nephropathy
Ticker: NVS
Executed On: Apr 26, 2024 at 02:45 PM EDT -
Discussing the phase 3 APPLAUSE-IgAN study results on Fabhalta (iptacopan) in patients with IgA Nephropathy
Ticker: NVS
Executed On: Apr 24, 2024 at 05:00 PM EDT -
A Third Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Mar 12, 2024 at 01:00 PM EDT -
A Second Look: Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Feb 02, 2024 at 09:00 AM EST -
A Second Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Feb 01, 2024 at 04:30 PM EST -
Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LLY, LNTH, FUSN
Executed On: Jan 26, 2024 at 08:00 AM EST -
Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Jan 24, 2024 at 12:30 PM EST -
A Second Look: Discussing the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Ticker: NVS
Executed On: Jan 15, 2024 at 12:00 PM EST -
A Second View: Taking a look at the current treatment landscape for C3G and the potential of iptacopan, an oral, Factor B inhibitor in reducing proteinuria being developed by Novartis.
Ticker: NVS
Executed On: Jan 04, 2024 at 02:30 PM EST -
Taking a look at the current treatment landscape for C3G and the potential of iptacopan, an oral, Factor B inhibitor in reducing proteinuria being developed by Novartis.
Ticker: NVS
Executed On: Jan 04, 2024 at 11:30 AM EST -
Discussing the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Ticker: NVS
Executed On: Dec 18, 2023 at 09:00 AM EST -
A Second Opinion: Discussing the potential use of Novartis' Cosentyx for patients with hidradenitis suppurativa (HS)
Ticker: NVS
Executed On: Dec 08, 2023 at 11:15 AM EST -
Discussing the potential use of Novartis' Cosentyx for patients with hidradenitis suppurativa (HS)
Ticker: NVS
Executed On: Dec 01, 2023 at 08:15 AM EST -
A Third Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 22, 2023 at 05:05 PM EST -
A Second Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 20, 2023 at 11:00 AM EST -
Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 17, 2023 at 12:35 PM EST -
A second look: Delving into the data on Novartis' Pluvicto as a treatment for mCRPC presented at ESMO 2023.
Ticker: NVS
Executed On: Nov 03, 2023 at 09:00 AM EDT -
Delving into the data on Novartis' Pluvicto as a treatment for mCRPC presented at ESMO 2023.
Ticker: NVS
Executed On: Nov 01, 2023 at 03:00 PM EDT -
Discussing the potential of high dose aflibercept (Eylea)
Tickers: REGN, NVS
Executed On: Sep 14, 2023 at 03:30 PM EDT -
A third look: Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 30, 2023 at 11:00 AM EDT -
A second look: Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 25, 2023 at 03:00 PM EDT -
Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 24, 2023 at 07:15 PM EDT -
Discussing the potential of aflibercept (Eylea) biosimilars and specifically speaking on the Mylight clinical study from Sandoz and Novartis
Tickers: NVS, REGN
Executed On: Aug 23, 2023 at 05:00 PM EDT -
A third look at standard of care and the potential use of remibrutinib as part of treatment for CSU in light of the positive top-line results from the Phase III REMIX-1 and REMIX-2 studies
Ticker: NVS
Executed On: Aug 18, 2023 at 12:30 PM EDT -
A second look at standard of care and the potential use of remibrutinib as part of treatment for CSU in light of the positive top-line results from the Phase III REMIX-1 and REMIX-2 studies
Ticker: NVS
Executed On: Aug 17, 2023 at 11:30 AM EDT -
A look at standard of care and the potential use of remibrutinib as part of treatment for CSU in light of the positive top-line results from the Phase III REMIX-1 and REMIX-2 studies
Ticker: NVS
Executed On: Aug 15, 2023 at 04:15 PM EDT -
A Second Look: Discussing the current treatment landscape for Sjögren's syndrome and the potential of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome.
Ticker: NVS
Executed On: Aug 10, 2023 at 10:00 AM EDT -
Discussing the current treatment landscape for Sjögren's syndrome and the potential of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome.
Ticker: NVS
Executed On: Aug 09, 2023 at 12:00 PM EDT -
Discussing the potential of Novartis' gene therapy, Zolgensma (onasemnogene abeparvovec) in spinal muscular atrophy and the data for the LTFU studies
Ticker: NVS
Executed On: Aug 07, 2023 at 01:30 PM EDT -
A Second Opinion: Gaining insight into the use of Adakveo following the EMA recommendation to revoke authorization.
Ticker: NVS
Executed On: Jul 13, 2023 at 10:15 AM EDT -
Discussing the potential Cyanotriazoles in treating sleeping sickness and Chagas disease.
Ticker: NVS
Executed On: Jul 12, 2023 at 03:00 PM EDT -
A Third Opinion: Discussing the potential of Chinook's Atrasentan, currently in development for the treatment of IgAN
Tickers: NVS, KDNY
Executed On: Jun 22, 2023 at 04:00 PM EDT -
A Second Opinion: Discussing the potential of Chinook's Atrasentan, currently in development for the treatment of IgAN
Tickers: NVS, KDNY
Executed On: Jun 21, 2023 at 02:30 PM EDT -
Gaining insight into the use of Adakveo following the EMA recommendation to revoke authorization.
Ticker: NVS
Executed On: Jun 21, 2023 at 11:00 AM EDT -
Discussing the potential of Chinook's Atrasentan, currently in development for the treatment of IgAN
Tickers: NVS, KDNY
Executed On: Jun 20, 2023 at 03:00 PM EDT -
Discussing the nationwide shortage of chemotherapy drugs Cisplatin and Carboplatin
Ticker: NVS
Executed On: Jun 15, 2023 at 04:00 PM EDT -
A look at the 4 year data on Evrysdi as a treatment for spinal muscular atrophy
Tickers: RHHBY, PTC, NVS
Executed On: May 10, 2023 at 04:00 PM EDT -
A second look at the PNH treatment landscape and the potential use of Iptacopan (oral, selective factor B inhibitor) currently in phase 3 APPLY-PNH trial by Norvatis presented at the ASH Conference
Ticker: NVS
Executed On: Mar 09, 2023 at 04:00 PM EST -
A look at the PNH treatment landscape and the potential use of Iptacopan (oral, selective factor B inhibitor) currently in phase 3 APPLY-PNH trial by Norvatis presented at the ASH Conference
Ticker: NVS
Executed On: Mar 06, 2023 at 12:00 PM EST -
A Second Perspective: Checking in with a prescriber of Novartis' Pluvicto for the treatment of metastatic castration-resistant prostate cancer.
Ticker: NVS
Executed On: Feb 22, 2023 at 08:00 AM EST -
Checking in with a prescriber of Novartis' Pluvicto for the treatment of metastatic castration-resistant prostate cancer.
Ticker: NVS
Executed On: Jan 20, 2023 at 02:00 PM EST -
A Second look at Phase 2 trial data of Kisqali(ribociclib)
Ticker: NVS
Executed On: Dec 16, 2022 at 11:00 AM EST -
A First look at Phase 2 trial data of Kisqali(ribociclib)
Ticker: NVS
Executed On: Dec 15, 2022 at 11:00 AM EST -
Examining the recent top-line phase 3 data on iptacopan by Novartis in treating paroxysmal nocturnal hemoglobinuria
Ticker: NVS
Executed On: Nov 04, 2022 at 01:00 PM EDT -
Discussing Leqvio as a new pcsk9-inhibiting alternative for high LDL cholesterol in HEFH or ASCVD insufficiently controlled by statins.
Ticker: NVS
Executed On: Sep 21, 2022 at 06:15 PM EDT -
A Fourth look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, NVS, IONS
Executed On: Aug 18, 2022 at 04:00 PM EDT -
A look at the prescribing habits of Jardiance to reduce the risk of cardiovascular death and hospitalization due to heart failure
Tickers: BOEHRINGER INGELHEIM, NVS
Executed On: Aug 18, 2022 at 01:00 PM EDT -
A Third Look at the approved Abbvie's Humira and the general landscape of HS treatments on the horizon
Tickers: ABBV, NVS, ANAB
Executed On: Aug 05, 2022 at 01:00 PM EDT -
A Second Look at the approved Abbvie's Humira and the general landscape of HS treatments on the horizon
Tickers: ABBV, NVS, ANAB
Executed On: Aug 05, 2022 at 08:30 AM EDT -
A Look at the use of Abbvie's Humira as an approved treatment for Hidradenitis Suppurativa and the landscape of potential new treatments on the horizon
Tickers: ABBV, NVS
Executed On: Aug 04, 2022 at 01:00 PM EDT -
A Third View: Discussing Pluvicto for the treatment of metastatic or castrate-resistant prostate cancer in light of its recent FDA approval.
Ticker: NVS
Executed On: Apr 14, 2022 at 02:30 PM EDT -
A Second View: Discussing Pluvicto for the treatment of metastatic or castrate-resistant prostate cancer in light of its recent FDA approval.
Ticker: NVS
Executed On: Apr 04, 2022 at 12:00 PM EDT -
Discussing Pluvicto for the treatment of metastatic or castrate-resistant prostate cancer in light of its recent FDA approval.
Ticker: NVS
Executed On: Mar 29, 2022 at 04:30 PM EDT -
Discussing Leqvio (Inclisiran) in treating high LDL cholesterol associated with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) - 3rd look
Ticker: NVS
Executed On: Feb 25, 2022 at 01:00 PM EST -
Discussing Leqvio (Inclisiran) in treating high LDL cholesterol associated with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) - 2nd look
Ticker: NVS
Executed On: Feb 17, 2022 at 06:00 PM EST -
Discussing Leqvio (Inclisiran) in treating high LDL cholesterol assocaited with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH)
Ticker: NVS
Executed On: Feb 11, 2022 at 04:30 PM EST
Upcoming & Overdue Catalysts (NVS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (NVS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
